<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113654</url>
  </required_header>
  <id_info>
    <org_study_id>WI_SleepIPF_169/2015</org_study_id>
    <nct_id>NCT05113654</nct_id>
  </id_info>
  <brief_title>Sleep Disorders in Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Sleep Disorders in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wissenschaftliches Institut Bethanien e.V</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wissenschaftliches Institut Bethanien e.V</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This diagnostic observational study was conducted to (1) investigate the prevalence of&#xD;
      sleep-related breathing disorders and other sleep disorders in idiopathic pulmonary fibrosis&#xD;
      in comparison to COPD, (2) identify characteristics of symptomatic and prognostic&#xD;
      significance in idiopathic pulmonary fibrosis with/without sleep disorders, and (3) evaluate&#xD;
      different tools for their ability to assess the risk of co-existing sleep disorders in&#xD;
      idiopathic pulmonary fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2016</start_date>
  <completion_date type="Actual">June 7, 2019</completion_date>
  <primary_completion_date type="Actual">June 7, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with any kind of sleep disorder according to the International Classification of Sleep Disorders (ICSD-3)</measure>
    <time_frame>For individual assessment of sleep disorders: one night (between 5 and 9 hours), for overall number of patients: entire study duration (37 months)</time_frame>
    <description>Sleep disorders defined by the International Classfication of Sleep Disorders are diagnosed by a single sleep study (polysomnography or polygraphy), lasting between 5 and 9 hours for each individual participant. The number of patients for whom at least one sleep disorder is diagnosed, is used to calculate the prevalence of sleep disorders among each patient group.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">78</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>IPF</arm_group_label>
    <description>Patients with idiopathic pulmonary fibrosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <description>Patients with chronic obstructive pulmonary disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>Healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sleep study</intervention_name>
    <description>Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders</description>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>IPF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants were recruited from clinical routine patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;=18 years&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  IPF cohort: Documented history of IPF with definite or possible UIP pattern and signs&#xD;
             of emphysema below 10% by HRCT (IPF diagnosis according to 2011 ATS/ERS IPF&#xD;
             guidelines)&#xD;
&#xD;
          -  COPD cohort: Documented history of COPD Stage II Group A or B, Stage III or IV, Group&#xD;
             C or D (GOLD 2014)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Long-term oxygen therapy&#xD;
&#xD;
          -  Heart failure NYHA stages III and IV&#xD;
&#xD;
          -  Left ventricular ejection fraction â‰¤ 45%&#xD;
&#xD;
          -  Pregnancy and/or lactation&#xD;
&#xD;
          -  Acute and/or life-threatening illness (instable angina pectoris, acute pulmonary&#xD;
             arterial embolism, myocardial infarction, malignant tumor requiring treatment)&#xD;
&#xD;
          -  Current drug or alcohol abuse&#xD;
&#xD;
          -  Any medical, psychological or other condition impairing the patient's ability to&#xD;
             provide informed consent&#xD;
&#xD;
          -  IPF cohort: Acute exacerbation of IPF&#xD;
&#xD;
          -  IPF cohort: Concomitant lung/airway diseases other than IPF (signs of emphysema &gt;10%&#xD;
             by HRCT)&#xD;
&#xD;
          -  COPD cohort: Acute exacerbation of COPD&#xD;
&#xD;
          -  COPD cohort: Concomitant lung/airway diseases other than COPD (e.g. Asthma bronchiale)&#xD;
&#xD;
          -  Healthy cohort: Documented history of structural airway or lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winfried Randerath, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wissenschaftliches Institut Bethanien e.V</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wissenschaftliches Institut Bethanien e.V.</name>
      <address>
        <city>Solingen</city>
        <state>NRW</state>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

